本文对严重再生障碍性贫血(简称再障)随机用早期骨髓移植与常规治疗进行分组比较,取得一定的进展。全部均为初诊病例,符合再障的诊断。严重再障的指标,至少具备下列3项中的2项:(1)中性粒细胞<500/立方毫米,(2)血小板<20,000/立方毫米及 (3)网织红细胞<1％(经血球压积校正)。而从骨髓活检,增生必须显著低下(<正常细胞数的25％)或中度低下(为正常细胞数的25～50％和<剩余造血细胞的30％)。同时排除因中性粒细胞缺乏、恶性疾病、白血病前期、骨髓纤维化或先天性全血细胞减少症所致的全血细胞减少。分两组进行治疗:(1)作骨髓移植的病例:于移植前用环磷酰胺、抗淋巴细胞球蛋白(或血清)、甲基苄肼等进行免疫抑制。确诊后的17～100天(平均 In this paper, we compared the randomized treatment of early bone marrow transplantation and routine treatment of severe aplastic anemia (referred to as aplastic anemia), and made some progress. All are newly diagnosed cases, in line with the diagnosis of aplastic anemia. Severe aplastic anemia indicators, at least have the following three in 2: (1) neutrophils <500 / mm3, (2) platelets <20,000 / mm3 and (3) reticulocytes <1% Hematocrit correction). From bone marrow biopsies, however, proliferation must be significantly reduced (<25% of normal cells) or moderately low (25-50% of normal cells and <30% of remaining hematopoietic cells). At the same time exclude due to neutropenia, malignant disease, pre-leukemia, myelofibrosis or congenital pancytopenia caused by pancytopenia. Divided into two groups for treatment: (1) for bone marrow transplantation cases: before transplantation with cyclophosphamide, anti-lymphocyte globulin (or serum), procarbazine and other immunosuppression. 17 to 100 days after diagnosis (average